Company intelligence / Profile preview

Xytis

Irvine, California, United Statesbloomberg.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Xytis developed small molecule therapeutics for central nervous system disorders. Its lead programs included Anatibant (XY2405), a bradykinin B2 antagonist in Phase 2 trials for traumatic brain injury with Fast Track and Orphan Drug status in the US/EU, and Neboglamine (XY2401), targeting cognitive/negative symptoms of schizophrenia in early clinical studies. Both compounds showed good safety/tolerability profiles in initial trials. The company also had preclinical allosteric modulators of GABA-A and nicotinic acetylcholine receptors.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

anatibant

Discontinued

Partnerships

No major pharmaceutical partnerships disclosed; some partnering interest noted for preclinical programs as per management statements

Beyond the preview

Go deeper on Xytis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xytis.

Explore the full profile